Briefing for Investor call - TheraPharm GmbH Acquisition
Filed with ASX · · 17 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallDisclaimer The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (“Telix”) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document
Telix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Telix Pharmaceuticals
- Acquisition of TheraPharm GmbH - Investor Call
- Telix Acquires TheraPharm GmbH
- Prostate Cancer Therapy FDA Meeting Update
- NDA for Prostate Cancer Imaging accepted by US FDA
- Investor Briefing - Asia Strategy
Later from Telix Pharmaceuticals
- Telix and DuChemBio - South Korea Partnership
- ProstACT Phase III Study Clinical Development Update
- TGA Priority Review Granted for Prostate Cancer Imaging
- FDA New Drug Application for TLX591-CDx Proceeds to Review
- Telix Completes Acquisition of TheraPharm GmbH
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals